Announcement

Collapse
No announcement yet.

Front Immunol . Increased incidence of seronegative autoimmune hepatitis in children during SARS-CoV-2 pandemia period

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Front Immunol . Increased incidence of seronegative autoimmune hepatitis in children during SARS-CoV-2 pandemia period

    Front Immunol


    . 2024 Sep 11:15:1445610.
    doi: 10.3389/fimmu.2024.1445610. eCollection 2024. Increased incidence of seronegative autoimmune hepatitis in children during SARS-CoV-2 pandemia period

    Muriel Schmutz 1 , Suzanne Chartier 2 , Thierry Leblanc 3 , Charlotte Mussini 2 , Antoine Gardin 1 4 5 , Emmanuel Gonzales 1 4 5 , Anne-Marie Roque-Afonso 4 6 , Solene Le Cam 7 , Geraldine Hery 8 , Benedicte Neven 9 10 , Ramy Charbel 11 , Jean-Pierre Vartanian 12 , Emmanuel Jacquemin 1 4 5 , Guillaume Morelle 13 14 , Marion Almes 1 4 5



    AffiliationsAbstract

    Background: Seronegative autoimmune hepatitis in children is a rare but potentially severe disease, sometimes requiring liver transplantation. This type of hepatitis may be associated with various immunological and hematological disorders, ranging from isolated lymphopenia to aplastic anemia. Precise pathophysiological mechanisms are still unknown, but the role of viruses cannot be excluded, either as directly pathogenic or as triggers, responsible for an inappropriate immune stimulation. Having the impression of an increasing number of seronegative autoimmune hepatitis since the beginning of SARS-CoV-2 pandemia period, we hypothesized that SARS-CoV-2 virus could be an infectious trigger.
    Methods: We conducted a retrospective, observational, descriptive study about children with seronegative autoimmune hepatitis, in a tertiary care center, between 2010 and 2022.
    Results: Thirty-two patients were included. The overall incidence of seronegative autoimmune hepatitis increased 3.3-fold in 2020-2022, during the SARS-CoV-2 pandemia period (16 patients in 2.8 years) compared with 2010-2019 the pre pandemia period (16 patients in 9 years). Patients' clinical and biochemical liver characteristics did not differ between the two periods. Hematological damages were less severe during the pandemia period. Immunological studies revealed a dysregulated immune response. The initiation of immunosuppressive therapy (corticosteroids ± cyclosporine) was earlier during the pandemia period than before.
    Conclusion: In cases of undetermined acute hepatitis, an immune-mediated origin should be considered, prompting a liver biopsy. If the histological aspect points to an immune origin, immunosuppressive treatment should be instituted even though autoimmune hepatitis antibodies are negative. Close hematological monitoring must be performed in all cases. The 3.3-fold increase of cases during the SARS-CoV-2 pandemia will need to be further analyzed to better understand the underlying immunological mechanisms, and to prove its potential involvement.

    Keywords: aplastic anemia; dysimmunity; immunosuppressive treatment; pediatric seronegative autoimmune hepatitis; severe acute respiratory syndrome coronavirus 2.

Working...
X